Literature DB >> 34718207

Knowledge-based approaches to drug discovery for rare diseases.

Vinicius M Alves1, Daniel Korn2, Vera Pervitsky2, Andrew Thieme2, Stephen J Capuzzi2, Nancy Baker3, Rada Chirkova4, Sean Ekins5, Eugene N Muratov6, Anthony Hickey7, Alexander Tropsha8.   

Abstract

The conventional drug discovery pipeline has proven to be unsustainable for rare diseases. Herein, we discuss recent advances in biomedical knowledge mining applied to discovering therapeutics for rare diseases. We summarize current chemogenomics data of relevance to rare diseases and provide a perspective on the effectiveness of machine learning (ML) and biomedical knowledge graph mining in rare disease drug discovery. We illustrate the power of these methodologies using a chordoma case study. We expect that a broader application of knowledge graph mining and artificial intelligence (AI) approaches will expedite the discovery of viable drug candidates against both rare and common diseases.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Data mining; Drug discovery; Informatics; Knowledge graphs; Rare diseases

Mesh:

Year:  2021        PMID: 34718207      PMCID: PMC9124594          DOI: 10.1016/j.drudis.2021.10.014

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   8.369


  95 in total

Review 1.  Drug repositioning: identifying and developing new uses for existing drugs.

Authors:  Ted T Ashburn; Karl B Thor
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  A call to arms against ultra-rare diseases.

Authors:  Stanley T Crooke
Journal:  Nat Biotechnol       Date:  2021-06-04       Impact factor: 54.908

Review 3.  Drug discovery and development for rare genetic disorders.

Authors:  Wei Sun; Wei Zheng; Anton Simeonov
Journal:  Am J Med Genet A       Date:  2017-07-21       Impact factor: 2.802

4.  Doing it All - How Families are Reshaping Rare Disease Research.

Authors:  Sean Ekins; Ethan O Perlstein
Journal:  Pharm Res       Date:  2018-08-16       Impact factor: 4.200

5.  Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil.

Authors:  Hugo W Moser; Gerald V Raymond; Shou-En Lu; Larry R Muenz; Ann B Moser; Jiahong Xu; Richard O Jones; Daniel J Loes; Elias R Melhem; Prachi Dubey; Lena Bezman; N Hong Brereton; Augusto Odone
Journal:  Arch Neurol       Date:  2005-07

Review 6.  Sildenafil: a review of its use in erectile dysfunction.

Authors:  H D Langtry; A Markham
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 7.  What is biomedical informatics?

Authors:  Elmer V Bernstam; Jack W Smith; Todd R Johnson
Journal:  J Biomed Inform       Date:  2009-08-13       Impact factor: 6.317

Review 8.  MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search.

Authors:  Noa Rappaport; Michal Twik; Inbar Plaschkes; Ron Nudel; Tsippi Iny Stein; Jacob Levitt; Moran Gershoni; C Paul Morrey; Marilyn Safran; Doron Lancet
Journal:  Nucleic Acids Res       Date:  2016-11-28       Impact factor: 16.971

9.  Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours.

Authors:  Remco J Molenaar; Robert J S Coelen; Mohammed Khurshed; Eva Roos; Matthan W A Caan; Myra E van Linde; Mathilde Kouwenhoven; Jos A M Bramer; Judith V M G Bovée; Ron A Mathôt; Heinz-Josef Klümpen; Hanneke W M van Laarhoven; Cornelis J F van Noorden; W Peter Vandertop; Hans Gelderblom; Thomas M van Gulik; Johanna W Wilmink
Journal:  BMJ Open       Date:  2017-06-10       Impact factor: 3.006

10.  Enhancing Seasonal Influenza Surveillance: Topic Analysis of Widely Used Medicinal Drugs Using Twitter Data.

Authors:  Ireneus Kagashe; Zhijun Yan; Imran Suheryani
Journal:  J Med Internet Res       Date:  2017-09-12       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.